Pipeline
FIMECS has the following pipelines.
- Target
- Target class
- Target Indication
- Discovery
- IND-enabling
- Clinical Studies
- Partner
Target：IRAK-M
Target class：pseudokinase
- Target Indication：Non-small cell lung cancer Pancreatic cancer, etc.
- Discovery IND-enabling Clinical Studies FIM-001
IRAK-M (interleukin 1 receptor associated kinase 3) belongs to the pseudokinase family and has been considered “undruggable”. It is known as a negative regulator of the MyD88-dependent TLR/IL1R pathway and is specifically expressed in myeloid cells to suppress excessive activation of innate immunity. IRAK-M degraders are expected to be attractive cancer immunotherapeutic agents with a mechanism of action that release immunosuppressive property in myeloid cells in cancer patients.
Target：TRIB1
Target class：pseudokinase
- Target Indication：Oncology
- Discovery IND-enabling Clinical Studies
TRIB1 (Tribbles homolog 1) belongs to pseudokinase family and has been con“idered "undruggable”. It is a cooperative gene for Hoxa9, an important leukemia-causing gene, and its expression is enhanced in many acute myeloid leukemia subtypes. TRIB1 degraders are expected to show efficacy against Hoxa9-dependent acute myeloid leukemia.
Target：Undisclosed
Target class：Undisclosed
- Target Indication：Oncology
- Discovery IND-enabling Clinical Studies
Undisclosed
Target：Undisclosed
Target class：Undisclosed
- Target Indication：Oncology
- Discovery IND-enabling Clinical Studies
Undisclosed